

Home Health Line Tool

Quick reference guide to the CDC’s COVID-19 vaccination recommendations

Use this reference sheet as a guide for current CDC guidance and recommendations pertaining to the 2024-2025 COVID-19 vaccinations. Information in this sheet was current at the time of publication. Check the CDC’s website frequently for updates.

As of Oct. 31, the CDC recommends:

People aged 65 and older, who are vaccinated under the routine schedule:

- Receive two doses of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax or Pfizer-BioNTech) separated by six months (minimum interval two months) regardless of vaccination history.
 - Unvaccinated people who initiate vaccination with 2024–2025 Novavax COVID-19 vaccine are recommended to receive two doses of Novavax 3-8 weeks apart followed by a third dose of any COVID-19 vaccine six months later.

People ages six months and older who are moderately or severely immunocompromised are recommended to receive:

- **Unvaccinated:** A multidose initial series with an age-appropriate COVID-19 vaccine and one dose six months (minimum interval two months) after completion of the initial series.
 - May receive additional doses under shared clinical decision making.
- **Previously completed the multidose initial series:** two age-appropriate doses of 2024–2025 COVID-19 vaccine six months (minimum interval two months) apart.
 - May receive additional doses under shared clinical decision making.

COVID-19 recommended vaccination schedule by age/vaccination history

Children aged six months to four years:

If unvaccinated:

- They should receive a multidose initial series with a 2024–2025 mRNA vaccine.

If they have previously completed an initial series:

- They should receive one dose of a 2024–2025 mRNA vaccine from the same manufacturer as the initial series.

People aged five to 64 years:

- Should receive one dose of an age-appropriate 2024–2025 COVID-19 vaccine.
- People aged 12–64 years who are unvaccinated and receive the 2024–2025 Novavax COVID-19 Vaccine for initial vaccination should receive 2 doses of 2024–2025 Novavax COVID-19 vaccine.

People aged 65 years and older:

- Should receive two doses of any 2024–2025 COVID-19 vaccine, spaced six months (minimum interval two months) apart.
- Those who are unvaccinated and receive Novavax COVID-19 Vaccine for initial vaccination should receive two doses of 2024–2025 Novavax COVID-19 vaccine 3-8 weeks apart followed by a third dose of any 2024–2025 COVID-19 vaccine dose six months after the second dose.

COVID-19 vaccination recommendations for people who are moderately or severely immunocompromised

If unvaccinated:

- They should receive a multidose initial series with an age-appropriate 2024–2025 COVID-19 vaccine and one dose of a 2024–2025 COVID-19 vaccine six months (minimum interval two months) after completing the initial series

If they previously completed an initial series:

- They should receive two doses of an age-appropriate 2024–2025 COVID-19 vaccine spaced six months (minimum interval two months) apart

Note: They may also receive additional age-appropriate 2024–2025 COVID-19 vaccine doses under shared clinical decision-making, per CDC guidance.

Source: The information displayed in these charts comes from the CDC’s website under the Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States section as of Nov. 19, 2024. This information is subject to change as the CDC updates their guidance and recommendations. To keep up with updates or for more information, visit, <https://tinyurl.com/5n7rnntx>.